Industry News

News from Chiesi

2023-06-29T15:17:17+02:00

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

News from Chiesi2023-06-29T15:17:17+02:00

News from Sanofi

2023-06-29T14:57:10+02:00

Sanofi dedicated their Fabry Awareness Month Campaign to highlighting the psychological impact of Fabry.

News from Sanofi2023-06-29T14:57:10+02:00

Fabry Outcome Survey- Final Report 2022

2023-06-29T11:44:31+02:00

I am pleased to introduce the final Fabry Outcome Survey (FOS) report for patients and caregivers, which is based on data collected within FOS from 5 October 2001 to 30 September 2022. The aim of this registry, funded by Takeda, was to collect information on patients with Fabry disease. [...]

Fabry Outcome Survey- Final Report 20222023-06-29T11:44:31+02:00

News from Freeline

2023-04-07T16:08:54+02:00

Freeline has made the difficult decision to not progress our Fabry disease program further

News from Freeline2023-04-07T16:08:54+02:00

News from Sanofi

2023-03-17T13:47:28+01:00

Orphanet Journal of Rare Diseases recently published an in-depth history of the Sanofi Rare Disease Registries.

News from Sanofi2023-03-17T13:47:28+01:00

Sad news from Fabry Korea

2023-03-17T13:41:33+01:00

It is with great sadness that we learned of the passing of BongKi Lim, Fabry Korea's chairman for the past 22 years. 

Sad news from Fabry Korea2023-03-17T13:41:33+01:00
Go to Top